Celgene turns to Nimbus on ‘highly prized’ I/O target — landing right in Bristol-Myers’ sweet spot
Celgene’s BD team is staying in gear ahead of the close of the $74 billion Bristol-Myers buyout. And this latest deal lands right in Bristol’s sweet spot.
Celgene execs have turned to their partners at Nimbus, bagging an option for their HPK1 inhibitor program. For now, they’re keeping the terms under wraps, but Celgene, as well as Bristol-Myers, are known for being generous when it comes to assets they really, really want.
Basic subscription required
Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.